SPRAVATO®

A fast-acting, FDA-approved treatment for treatment-resistant depression that targets brain pathways involved in mood regulation to help improve symptoms and support recovery.

Book a consultation

Is SPRAVATO® for your symptoms?

  • SPRAVATO® is a clinically proven, FDA-approved, highly researched treatment designed specifically for hard-to-treat depression.

  • SPRAVATO® works on a different brain pathway than traditional daily antidepressants to break the daily pill grind.

  • SPRAVATO® offers rapid symptom relief. Many patients experience a noticeable lift in depressive symptoms within the very first few treatments.

  • SPRAVATO® helps provide improved daily function. It will help regulate mood and restores mental clarity so you can get back to your normal routine.

What to Expect on Your Journey

Step 1: The Consultation

Evaluation & History: A thorough clinical review with a qualified provider to ensure you are a safe candidate.

Tailored Planning: A collaborative discussion to map out your goals and give you clear preparation steps for your first session.

Step 2: The Treatment Phase

The Induction Series: A standard initial protocol of two infusion sessions per week for four weeks.

The Experience: Relax for approximately 1–2 hours in a quiet, deeply comfortable environment.

Step 3: Maintenance & Integration

Sustained Results: A personalized maintenance plan designed to lock in your long-term breakthrough.

Ongoing Support: Continued guidance from your care team to help you integrate your results into daily life.

Start your journey now.

Book a consultation

Frequently Asked Questions

  • Ketamine is an anesthetic that has been used off-label for depression for years, typically administered via IV infusion.

    Esketamine is a refined molecule derived from ketamine, it's the active component responsible for the antidepressant effect.

    SPRAVATO® is the FDA-approved brand name esketamine nasal spray, manufactured by Janssen (Johnson & Johnson). Unlike IV ketamine, SPRAVATO® is FDA-cleared specifically for treatment-resistant depression and depressive symptoms in adults with suicidal ideation, and is covered by most major insurers.

  • SPRAVATO® is FDA-approved for two groups: adults with Treatment-Resistant Depression (TRD), meaning they haven't responded adequately to at least two antidepressants, and adults with Major Depressive Disorder who have active suicidal ideation with intent or behavior. It is always used alongside an oral antidepressant, not as a standalone treatment.

  • Treatment follows a structured schedule:

    1. Induction (Weeks 1–4): Two sessions per week

    2. Maintenance Phase 1 (Weeks 5–8): One session per week

    3. Maintenance Phase 2 (Week 9 onward): One session every one to two weeks, based on your response.

      Each appointment includes self-administering the nasal spray under clinical supervision, followed by a mandatory two-hour observation period before you can be cleared to leave.

  • The starting dose is 56mg. Based on your response and tolerability, your provider may increase it to 84mg. Your provider determines the right dose for you, it's not one-size-fits-all.

  • If SPRAVATO® doesn't provide sufficient relief or isn't a good fit, your provider will work with you on next steps. Other options may include TMS therapy, medication adjustments, or other interventions available at TSPC. You're never left without a path forward.

  • Yes, and you're required to. SPRAVATO® is only approved for use in combination with an oral antidepressant. Do not stop or change any medications without consulting your provider first.

  • No. SPRAVATO® is administered in a certified outpatient clinical setting, right here in our office. You self-administer the nasal spray under the supervision of our clinical staff, then rest in our observation area for two hours. You do not need to be hospitalized.

  • SPRAVATO® is FDA-approved for depression, not anxiety as a standalone diagnosis. However, many patients with depression also experience significant anxiety, and some report improvement in those symptoms as their depression lifts. Talk to your provider about your full symptom picture.

  • SPRAVATO® is covered by most major commercial insurers and Medicare when medical necessity criteria are met, typically documentation of treatment-resistant depression and failure of at least two antidepressants. Prior authorization is required. o ketamine or esketamine

    • Are pregnant or breastfeeding

    • Have uncontrolled hypertension

    • Have a history of psychosis or are currently experiencing psychotic symptoms-

    • Have active or unstable cardiovascular or cerebrovascular diseaseHave active or unstable cardiovascular or cerebrovascular disease

    Your provider will conduct a full medical and psychiatric evaluation before starting treatment.